Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. - Wikidata - awgldk - TriplyDB

Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy.

Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy.

http://www.wikidata.org/entity/Q37278903

about

Eligibility of real-life patients with COPD for inclusion in RCTs: a commentary.Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD): follow-up interviews on patient-centred outcomes.Chronic obstructive pulmonary disease guidelines in Europe: a look into the future.

P2860

Q42333511-35AB58F9-1E0B-482D-B0FE-25927755B6CC Q47125538-F0D58E69-0E40-415D-BB25-2B545750DFC4 Q47653653-C7C8425D-24AD-4B57-88ED-FF7E6872036B

P2860

Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy.

http://www.wikidata.org/entity/Q37278903

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 September 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Eligibility of real-life patie ...... acting bronchodilator therapy.

@en

Eligibility of real-life patie ...... acting bronchodilator therapy.

@nl

type

label

Eligibility of real-life patie ...... acting bronchodilator therapy.

@en

Eligibility of real-life patie ...... acting bronchodilator therapy.

@nl

prefLabel

Eligibility of real-life patie ...... acting bronchodilator therapy.

@en

Eligibility of real-life patie ...... acting bronchodilator therapy.

@nl

P1433

Q37278903-2C879D60-A45C-47B8-B5F2-90F504B9854C

P1476

Q37278903-A48689DD-E34A-4994-9FAA-39DCBB087110

P2093

Q37278903-208DAC37-A8E2-409F-A3B3-D854CD338203

Q37278903-623FC753-2AEF-4647-A319-A59F771F6D0D

Q37278903-76F0DFA7-0B2B-4D5C-AEC5-AD7288A84903

Q37278903-7E922545-65F1-4875-AFBD-94B48F58B020

P2860

Q37278903-0C639FB0-68FA-42E0-BE4E-5838B1C39A20

Q37278903-0CFBAE38-F559-4BF6-9764-ECB5EA5D229C

Q37278903-0E5FCF9A-22EC-4CB8-8C7B-7097640B2C65

Q37278903-0FD78681-BED8-4A1B-A0D9-27008CA165BA

Q37278903-154D3334-699F-490B-8285-CFD781D85B70

Q37278903-1F33D715-8769-4B0E-9011-218A57CCD7A3

Q37278903-219763B6-E63E-458D-8E26-E18E7D95FE34

Q37278903-28671CB6-AF59-4426-AD01-C72BEF660824

Q37278903-324B414B-227F-48F8-B21E-932965283EFE

Q37278903-365F2DBD-EEA2-443F-B688-B2B8F2759E9F

P2888

Q37278903-EC2E1353-8E86-49A2-8D27-BE257F8FA022

P304

Q37278903-EB8967CA-DC2A-4DF5-BEDA-27ACF711DE12

P31

Q37278903-660C55C6-6C5C-4C64-B3A4-E399F8F651AF

P356

Q37278903-4E0F21A6-5948-421B-8224-2E10474C06E9

P433

Q37278903-22D94AD7-1B2A-48AC-9785-4BA3E4B20B1E

P478

Q37278903-6F39AAFE-D05A-414F-B401-E866E1283E6E

P50

Q37278903-4520727F-C831-49DF-B581-A8EA4B3E4C03

P577

Q37278903-4A33548E-B720-4C44-8C27-53332E02DC66

P6179

Q37278903-819B8BB6-5345-40C5-A9DD-DCF11A9A3C40

P698

Q37278903-D913F186-4A81-443B-B755-F9A24B9C42CD

P932

Q37278903-777CC61B-D01C-4A84-8A28-74259560F5EE

P356

S12931-016-0433-5

P1433

Respiratory Research

P1476

Eligibility of real-life patie ...... acting bronchodilator therapy.

@en

P2093

David B Price

http://www.w3.org/2001/XMLSchema#string

David M G Halpin

http://www.w3.org/2001/XMLSchema#string

Helga Mikkelsen

http://www.w3.org/2001/XMLSchema#string

Marjan Kerkhof

http://www.w3.org/2001/XMLSchema#string

P2860

Real-world research and its importance in respiratory medicine

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

The effect of tiotropium on exacerbations and airflow in patients with COPD.

Asthma out of control? A structured review of recent patient surveys.

The external validity of published randomized controlled trials in primary care.

Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.

Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.

Tiotropium Respimat inhaler and the risk of death in COPD.

A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

P2888

s12931-016-0433-5

P304

120

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12931-016-0433-5

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Joan B. Soriano

P577

2016-09-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1009546325

http://www.w3.org/2001/XMLSchema#string

P698

27663386

http://www.w3.org/2001/XMLSchema#string

P932

5034631

http://www.w3.org/2001/XMLSchema#string